CIPROFLOXACIN INJECTION SOLUTION

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

CIPROFLOXACIN (CIPROFLOXACIN LACTATE)

Saatavilla:

BAXTER CORPORATION

ATC-koodi:

J01MA02

INN (Kansainvälinen yleisnimi):

CIPROFLOXACIN

Annos:

2MG

Lääkemuoto:

SOLUTION

Koostumus:

CIPROFLOXACIN (CIPROFLOXACIN LACTATE) 2MG

Antoreitti:

INTRAVENOUS

Kpl paketissa:

100ML/200ML

Prescription tyyppi:

Prescription

Terapeuttinen alue:

QUINOLONES

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0123207007; AHFS:

Valtuutuksen tilan:

DORMANT

Valtuutus päivämäärä:

2018-07-06

Valmisteyhteenveto

_CIPROFLOXACIN INJECTION _
_ _
_Page 1 of 62 _
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CIPROFLOXACIN
INJECTION
CIPROFLOXACIN 0.2 % INTRAVENOUS INFUSION
CIPROFLOXACIN 0.2 % (AS LACTATE) IN 5 % DEXTROSE SOLUTION
STERILE
ANTIBACTERIAL AGENT
Baxter Corporation
Mississauga, Ontario
L5N 0C2
Date of Revision:
June 3, 2019
SUBMISSION CONTROL NUMBER: 224895
_CIPROFLOXACIN INJECTION _
_ _
_Page 2 of 62 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
3
SUMMARY PRODUCT INFORMATION
.......................................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................................
3
CONTRAINDICATIONS
..................................................................................................................
5
WARNINGS AND PRECAUTIONS
................................................................................................
6
PRECAUTIONS
...............................................................................................................................
10
ADVERSE REACTIONS
................................................................................................................
15
DRUG INTERACTIONS
.................................................................................................................
18
DOSAGE AND ADMINISTRATION
.............................................................................................
24
OVERDOSAGE
...............................................................................................................................
26
ACTION AND CLINICAL PHARMACOLOGY
...........................................................................
27
STORAGE AND STABILITY
........................................................................................................
32
SPECIAL HANDLING INSTRUCTIONS
......................................